The Human Macrophage Inflammatory Protein-1α (CCL3) (Hu MIP-1α) ELISA quantitates Hu MIP-1α in human serum, plasma, cell culture supernatants or other body fluids. The assay will exclusively recognize both natural and recombinant Hu MIP-1α.
Principle of the method
The Human MIP-1α solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the binding of the second (detector) antibody to the target on a different epitope from the capture antibody. An antibody conjugated with enzyme binds the formed sandwich. After incubation and washing steps to rid the microplate of unbound substances, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen.
Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.
CCL3 (MIP1a, Macrophage Inflammatory Protein-1 alpha, MIP-1 alpha) has a molecular weight of approximately 8 kDa, belongs to the family of chemotactic cytokines, and is involved in chemotactic and proinflammatory effects, and homeostasis. CCL3 is produced by lymphocytes, macrophages and dendritic cells, and is involved in inflammatory response of blood monocytes and tissue macrophages. Also, CCL3 can exist as a naturally occurring heterodimer with MIP-1beta and has been shown to have antiviral activity against HSV-1. CCL3 protein can bind with high affinity to the CCR1 and CCR5 receptors.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.